Syndemics: intersecting STI and **HIV** epidemics and the opportunity to improve diagnosis and prevention in Malawi

Sarah Rutstein

**Division of Infectious Diseases** 

### Outline

Tacking and jibing (aka: how I got here)

Adapting to an evolving epidemic

Syndemics – STIs & HIV

STIs in Malawi – what are we missing?

### Outline

Tacking and jibing (aka: how I got here)

Adapting to an evolving epidemic

Syndemics – STIs & HIV

Genomics of genital ulcer disease

STIs in Malawi – what are we missing?

Integrating HIV prevention and STI services

### Outline

Tacking and jibing (aka: how I got here)

Adapting to an evolving epidemic

Syndemics – STIs & HIV

STIs in Malawi – what are we missing?

Global health is local health



Bailey-Boushay House, Seattle (2000-2003)







Bailey-Boushay House, Seattle (2000-2003)



2003-2007




### Malawi's HIV epidemic




### Malawi's HIV epidemic


MALAWI Progress towards 90 90 90 targets (all ages)




### Malawi's HIV epidemic

Progress towards 90 90 90 targets (all ages) MALAWI







Virally


Source: PEPFAR (2016) 'PEPFAR Latest Global Results'

÷


·\*\*

Sec. 1.

# Finding, testing, and linking the "unaware"



Targeted testing to high-risk social and sexual networks



Adapting case finding and prevention to local context: what works

Assisted partner notification (APN)

Social network recruitment

Acute HIV infection (AHI) screening

Tracing and offering testing to named sexual partners of newly diagnosed (or persons with high viral loads)

Using clinic- (or community-) based "seeds" to recruit persons in their sexual or social networks for HIV testing

Early and brief phase of infection with high viral loads, disproportionate role in new infections


# Provider or contract notification 2x as effective as passive

Enrolled 245 index patients

302 names sexual partners (252 with locator information)

Active notification arms 2x as likely to have returning partners

107 HIV Testing & Counseling 67/107 (64%) were HIV-infected 54/67 (81%) newly diagnosed




**FIGURE 1.** Shows the cumulative proportion of partners of partners presenting for testing for each method of partner notification. Time to partner visit is the number of days following the index patient enrollment visit.

Brown, L. et al., HIV Partner Notification Is Effective and Feasible in Sub-Saharan Africa: Opportunities for HIV Treatment and Prevention, JAIDS, 2011

Social contacts from STI clinic effective "seeds" for identifying new HIV

Contacts of HIV-infected clinic seeds >HIV prevalence than contacts of community seeds


NNT(test): 8-10 clinic seeds



Social contact recruitment in a generalized epidemic among persons with biological evidence of risk – newly diagnosed HIV and/or STI


30% of contacts of persons with AHI had HIV

### Acute HIV infection (AHI)






### Frequently detected AHI at STI clinic



AHI Risk Score:	Points
Discordant rapid antib	ody tests: 4
Fever, body ache, >1 p	artner: 1 (each)
Diarrhea, GUD :	2 (each)

Powers et al., Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm, *AIDS*, 2007

### Frequently detected AHI at STI clinic



Highly selected patient population (stay tuned)






### Syndemic bacterial STI/HIV: stronger together

Biological, behavioral, and epidemiological interactions

STIs enhancing efficiency of transmission via infectiousness (higher genital VL) or susceptibility

Mucosal inflammation and ulceration → exposed epithelium with concentrated inflammatory cells



Weiler et al., Genital Ulcers Facilitate Rapid Viral Entry and Dissemination following Intravaginal Inoculation with Cell-Associated Simian Immunodeficiency Virus SIVmac239, *Journal of Virology*, 2008

### Epidemiological synergy

#### ...so if we treat STIs, can we control HIV??

Study (author,	Intervention	Study design	Primary outcome	Study population (region)	Results
year)		DCT		Como dia condonat	No offect en UN/temperation
Celum et al 2010	Suppressive acyclovir to	RCT	HIV transmission		No effect on HIV transmission
		DOT		heterosexual, SSA	73% reduction in genital ulcers due to HSV-2 tx group
Celum et al, 2008	Suppressive acyclovir to	RCT	HIV acquisition	HIV-negative women and	No reduction in HIV-1 acquisition
	reduce HIV-1 acquisition			MSM, SSA, Peru, USA	47% decrease in incidence of genital ulcers in tx group
Grosskurth et al,	Establishment of STD	RCT	HIV/STI incidence	Adults (aged 15-54),	- Reduced HIV incidence (RR: 0.58, CI 0.42, 0.79)
1995	reference clinic, staff training,			Tanzania	- STD prevalence consistently lower in intervention group, but
					not statistically significant
					<ul> <li>Symptomatic urethritis (men) reduced in intervention vs</li> </ul>
					comparison (RR: 0.49, CI, 0.09, 2.55)
Wawer et al, 1999	Intensive STD control via	RCT	HIV-1 incidence	Adults in Rakai, Uganda	- no difference in HIV-1 incidence
	home-based mass antibiotic				- reduced syphilis (RR: 0.8, CI 0.71, 0.89) and trichomoniasis
	treatment				(RR 0.59, CI 0.38, 0.91) in intervention group
Kamali et al, 2003	Information/education +/-	Community-	HIV-1 incidence	Adults, Uganda	- no difference in HIV incidence
	improved management of	randomized study			- lower HSV2 incidence in intervention
	STIs vs standard				- no difference in incidence of chlamydia between groups
Kaul et al, 2004	Monthly antibiotic	RCT	HIV-1 incidence	Female sex workers,	- no difference in HIV-1 incidence
	prophylaxis (azithromycin)			Nairobi, Kenya	- reduced incidence of gonorrhea, Chlamydia trachomatis,
					and Trichomonas vaginalis
Ghys, et al, 2001	Once monthly STD test/ tx or	RCT	HIV-1	Female sex workers, Cote	- no difference in HIV seroconversion, chlamydia, or genital
	intensive strategy with		seroconversion	d'Ivoire	ulcers rate between arms
	examination regardless of				- decrease in N. gonorrhoeae (14 to 5%, p<0.005) and T.
	symptoms				vaginalis (24 to 11%, p<0.001)
Gregson et al, 2007		Cluster RCT	Feasibility and	Adults, Zimbabwe	- reduced HIV-1 incidence and increased cessation of STI
	education, condoms, and STI		, HIV-1 incidence		symptoms among males in the intervention communities who
	tx and counseling services				attended program meetings
Watson-Jones et	Suppressive acyclovir	RCT	HIV incidence	Female sex workers,	- no between group difference in HIV-1 incidence or genital
al., 2008	treatment			Tanzania	ulceration at 1.5 year follow-up
	val; MSM: men who have sex v	vith men; RR: ra <u>te rati</u>	o; SSA: sub-Sa <u>hara</u>	n Africa; USA: United States	· · · · ·


### **Enter Treatment as Prevention**

Research (and research dollars) shifted away from STIs as a strategy for HIV control

ART effectively interrupts transmission even in setting of concomitant STI (despite detectable virus in genital tracts)

Despite 1 million incident *curable* STIs occur worldwide each day, little progress in diagnostics or prevention strategies

### STI burden and diagnosis in Malawi




#### Sexually transmitted infections (STIs) and symptoms

Respondents who have ever had sex are asked whether they had an STI or symptoms of an STI (a bad-smelling, abnormal discharge from the vagina/penis, a genital sore, or an ulcer) in the 12 months before the survey.


Sample: Women and men age 15-49

### STIs at Bwaila clinic (2017) (n=15,223)



### Syndromic Management

Implemented in early 1990s Relies on subjective assessment of symptoms




Majority of curable STIs are asymptomatic and thus missed, *particularly among women* 

→ implications for fertility, partner tracing/testing/treatment
 Poor sensitivity (10-20%) as well as high false positive (up to 80% for some syndromes) → under and over treatment

 $\rightarrow$  antimicrobial resistance

### Syndromic Management: an update

Revised (June 2021) WHO guidelines recommend <u>management using quality-</u> <u>assured molecular assays, if</u> <u>available</u>



### Genomics of genital ulcer disease (G-GUD)

UNC CFAR-funded Development Award (2020)

Known enhanced risk of HIV transmission and acquisition

Most diagnosed as syphilis, herpes simplex virus, chancroid, lymphogranuloma venereum (LGV), or granuloma inguinale BUT nearly 1/3 have no identifiable infectious etiology

Understanding of etiology and epidemiology outdated and incomplete

### G-GUD: study design

Prospective observational cohort study

Consecutively enrolled persons ≥18 with moist, non-healing ulcer

Excluded persons with recent (30d) antibiotic use

Stratified by HIV sero-status and sex

Collected swab (ulcer and unaffected skin) and blood at baseline and then swabbed non-healing ulcers at 2-week follow-up

Main Objective: To examine the infectious etiology and clinical outcomes of GUD, as well as contemporaneous sexual risk behaviors, among persons with HIV (acute, recent, or chronic) or persons at high risk for HIV-infection in Malawi.

### G-GUD preliminary results: HIV

Enrolled 50 adults (31 males, 19 females) 18 HIV-seropositive (11 previously known positive, 7 new) 32 HIV-seronegative

### G-GUD preliminary results: HIV

Enrolled 50 adults (31 males, 19 females) 18 HIV-seropositive (11 previously known positive, 7 new) 32 HIV-seronegative

2 with acute HIV  $\rightarrow$  2/32 (6.3%) of seronegative patients

### G-GUD preliminary results: demographics

	HIV +, n (%)	HIV-* <i>,</i> n (%)
Age (median, IQR)	26.5 (22.5, 32)	26.5 (24, 41)
Marital status		
Never married	0	8 (25)
Married	13 (72)	18 (56)
Separated/divorced	4 (22)	6 (19)
Widowed	1 (6)	0
Education		
None	4 (22)	6 (19)
Primary (some or all)	8 (45)	20 (62)
Secondary (some or all)	6 (33)	6 (19)
Electricity at home (yes)	5 (28)	10 (31)
Travel in past 30 days**	2 (11)	2 (6)

\*includes persons with AHI

\*\* 2 HIV+ persons reported traveling to southern Malawi, and 2 HIV- reported traveling to northern Malawi

### G-GUD preliminary results: sexual behaviors

	HIV +, n (%)	HIV-* <i>,</i> n (%)
Contraception (asked of female participants)		
None	4 (44)	3 (33)
Implant	2 (22)	5 (56)
Injection/IUD/condom	3 (33)	0
On ART (among previous positives)	10 (90)	
Partners in past week (mean)	1.1	0.65
Partners in past month	3	5.3
Condom at last sex (yes)	3 (17)	2 (6)
Alcohol or drug use before last sex (yes)	6 (33)	6 (19)
Sexual partner with sore or blister in past month	8 (50)	8 (28)
Known HIV-infected partner in past month	7 (44)	2 (7)
Days of ulcer symptoms (median, IQR)	7 (7,14)	12 (7, 21)
Had sex since noticed ulcer	7 (39)	12 (38)
Ever exchanged sex for goods or money (yes)	12 (67)	15 (47)
History of similar ulcers	2 (11)	2 (6)

### G-GUD preliminary results: 2-week follow-up

45/50 retained for 2-week follow-up Most (59%) did not have any partners in intervening weeks 16 (36%) had 1 partner, 1 (2%) had 3 partners, and 1 (2%) had 10

13 (29%) reported symptoms were improving 31 (71%) reported symptoms had resolved

2 (5%) reported new ulcers since enrollment visit

### G-GUD next steps

Serology: HSV, syphilis (RPR  $\rightarrow$  titer, TPPA),

PCRs (genital swabs): herpes simplex virus-type 2, Haemophilus ducreyi, Chlamydia trachomatis, T. pallidum, Schistosoma, T. vaginalis, and other bacteria associated with GUD


Genomic analyses: 16S and ITS sequencing using DNA extraction


Photo examination

STIs & HIV → not just *what* we are missing but *who* we are missing



## Finding, testing, and linking the "unaware"...to HIV prevention





### Integrating services: one-stop-shops

We know:

STI services are a good place to screen for AHI

People who seek STI services, even if HIV negative, may also have high-risk sexual partners (at risk for or infected with HIV)

<u>We don't know:</u>

How best to integrate PrEP into STI care

Whether using APN effectively identifies other HIV-negative persons who could benefit from PrEP

#### Logical extension of STI services - PrEP

Daily oral PrEP reduces HIV acquisition risk by >90%\*

Current PrEP screening uses epidemiologic/self-reported risk profiling Incident STIs are an objective marker of unprotected sex and in high HIV prevalence settings like Malawi, a reasonable proxy for HIV risk

#### Logical extension of STI services - PrEP

Incorporating PrEP with STI care an efficient leveraging of existing infrastructure

High rates of incident STIs on PrEP (>30%), often asymptomatic, reinforces importance of <u>etiologic STI testing + PrEP care</u>...and may motivate retention?

Increasing evidence that incidence of "classical" STIs increases (even after controlling for testing frequency) after PrEP initiation

APN may bolster PrEP recruitment to high-risk persons not accessing STI services


#### Enhanced Integrated PrEP: a pilot

Funded through Physician Science Training Program (PSTP), DoM

Pilot study enrolling PrEP users from Lilongwe-STI clinic and using APN to identify/recruit PrEP-eligible partners and etiologic STI testing, regardless of symptoms

**Primary objective:** To examine the feasibility, acceptability, and effectiveness (PrEP uptake and persistence) of integrating an enhanced PrEP implementation strategy into an STI clinic (Bwaila STI) in Lilongwe, Malawi.

#### Enhanced Integrated PrEP: study design



#### Enhanced Integrated PrEP: study population

## Potential PrEP users (including index and named sexual partners) PrEP providers

STI clinic patient ("potential PrEP user"):

- i.  $\geq$ 15 years of age.
- ii. Eligible for PrEP according to Malawi PrEP guidelines
- iii. Presenting for care at STI clinic (primary presentation or referral from partner based on STI or HIV exposure)
- iv. Able to consent for study participation and willing to provide locator information for follow-up tracing

PrEP provider:

- i.  $\geq$ 18 years of age.
- ii. Duties relevant to integration or provision of PrEP and/or aPN at STI clinic

#### Schedule of Events

Evaluation	Baseline	Month		
		1	3	6
PrEP eligibility screen	X			
Rapid HIV antibody tests	Х	X	Х	X
Syndromic STI assessment <sup>1</sup>	Х	X	Х	X
PrEP risk assessment, adherence assessment and counseling	Х	Х	Х	X
Behavioral survey	Х	X	Х	X
HIV RNA testing	Х			
STI testing (urine/blood) <sup>2</sup>	Х		Х	X
Sexual partner elicitation <sup>3</sup>	Х	X	Х	X
In-depth interviews <sup>4</sup>	Х			

<sup>1</sup>if indicated based on clinical symptoms; <sup>2</sup> *Neisseria gonorrhea* and *Chlamydia trachomatis* via GeneXpert, syphilis (RPR), Hepatitis B at baseline only, if symptoms detected/reported at 1-month or interim study visit, participants may have etiologic testing completed; <sup>3</sup> at baseline (all) and then if incident STI detected; <sup>4</sup> In-depth interviews with PrEP users PrEP: pre-exposure prophylaxis; RPR: rapid plasma reagin; STI: sexually transmitted infection

#### Outcomes

- 1) Feasibility and acceptability of integrating enhanced PrEP delivery into existing STI clinic services among PrEP users and providers.
  - > Number and proportion of STI clinic patients eligible for PrEP
  - > Number and proportion of potentially eligible PrEP users referred for PrEP
  - Acceptability and feasibility assessed using modified validated measures among PrEP providers
  - In-depth interviews will further contextualize survey responses, referral rates, and patient uptake, identifying potential barriers and facilitators to integration of enhanced PrEP within STI clinics, and preferences for PrEP delivery and follow-up

#### Outcomes

- 1) Feasibility and acceptability of integrating enhanced PrEP delivery into existing STI clinic services among PrEP users and providers.
- 2) PrEP uptake and PrEP persistence when enhanced PrEP delivery is integrated into existing STI clinics
- 3) Feasibility, acceptability, and preferences for enhanced PrEP recruitment via assisted partner notification among PrEP users and providers.
- 4) PrEP uptake and PrEP persistence among referred sexual partners
- 5) Feasibility and acceptability of incorporating etiologic STI testing with PrEP among PrEP users and providers
- 6) Potential clinical utility of incorporating etiologic STI testing with PrEP care at an STI clinic

# Sometimes an opportunity presents itself...

Funding Opportunity Title

Innovative Models for Delivering PrEP and STI Services to Stop HIV in the United States (R61/R33 Clinical Trial Optional)

#### Sweet Home North Carolina



Disparities of PrEP in the Southern US Accounts for >50% of new HIV, but 33% of PrEP users


STI	NC National ranking (2019)
HIV	6 <sup>th</sup>
Chlamydia	6 <sup>th</sup>
Gonorrhea	9 <sup>th</sup>
Syphilis	15 <sup>th</sup>

Uptake disparities among young sexual and gender minority (YSGM) men of color, particularly in rural counties

STI/HIV syndemics track along demographics and geography, with high burden among rural YSGM

## Meet me where I am: study design

Multilevel intervention linking PrEP and STI services, addressing barriers at policy, clinic, provider, and user levels



Partnering with local health department STI clinics





Figure 3: Multilevel Intervention















**Irving Hoffman** Jon Juliano Mina Hosseinipour **Bill Miller** Mitch Matoga Jane Chen Edward Jere **Emily Ciccone** Alex Duncan Morris Weinberger **UNC Project-Malawi UNC ID** 

#### Funding:

UNC CFAR (P30 Al050410) T32 (Al007001) UNC PSTP/UNC DoM OGHE/Global Health Scholars

### Questions

